204 related articles for article (PubMed ID: 19576114)
1. [The statin dosage for achieving goal of cholesterol-lowering based on risk stratification in patients with ischemic cerebrovascular diseases].
Tan ZF; Guo YD; Xu AD; Yang WY; Fu YG; Wang TG
Zhonghua Nei Ke Za Zhi; 2009 Apr; 48(4):280-3. PubMed ID: 19576114
[TBL] [Abstract][Full Text] [Related]
2. Medium-intensity statin with ezetimibe versus high-intensity statin in acute ischemic cerebrovascular disease (MESIA): A randomized clinical trial.
Lv X; Liu X; Peng Y; Li W; Wang J; Chen X; Lei J; Tang C; Luo S; Mai W; Cai Y; Fan Q; Liu C; Zhang L
J Stroke Cerebrovasc Dis; 2024 May; 33(5):107647. PubMed ID: 38431112
[TBL] [Abstract][Full Text] [Related]
3. A multicentre, open study to assess the effect of individualizing starting doses of atorvastatin according to baseline LDL-C levels on achieving cholesterol targets: the Achieve Cholesterol Targets Fast with Atorvastatin Stratified Titration (ACTFAST-2) study.
Farsang C; Athyros V; Gaw A;
Curr Med Res Opin; 2007 Aug; 23(8):1945-56. PubMed ID: 17626713
[TBL] [Abstract][Full Text] [Related]
4. Achieving lipoprotein goals in patients at high risk with severe hypercholesterolemia: efficacy and safety of ezetimibe co-administered with atorvastatin.
Stein E; Stender S; Mata P; Sager P; Ponsonnet D; Melani L; Lipka L; Suresh R; Maccubbin D; Veltri E;
Am Heart J; 2004 Sep; 148(3):447-55. PubMed ID: 15389231
[TBL] [Abstract][Full Text] [Related]
5. A multicenter, eight-week treatment, single-step titration, open-label study assessing the percentage of Korean dyslipidemic patients achieving LDL cholesterol target with atorvastatin starting doses of 10 mg, 20 mg and 40 mg.
Lee CW; Baek SH; Hong TJ; Choi YJ; Kim YJ; Ahn TH; Ihm SH; Bae JH; Hong SJ; Kim DI; Ahn YK; Hur SH; Park DG; Choi DJ; Lee SU; Kim BS; Ryu KH; Jang YS; Lee SH; Seung KB; Kim HS
Cardiovasc Drugs Ther; 2010 Apr; 24(2):181-8. PubMed ID: 20383571
[TBL] [Abstract][Full Text] [Related]
6. High-dose atorvastatin after stroke or transient ischemic attack.
Amarenco P; Bogousslavsky J; Callahan A; Goldstein LB; Hennerici M; Rudolph AE; Sillesen H; Simunovic L; Szarek M; Welch KM; Zivin JA;
N Engl J Med; 2006 Aug; 355(6):549-59. PubMed ID: 16899775
[TBL] [Abstract][Full Text] [Related]
7. Intensive lipid lowering with atorvastatin in patients with stable coronary disease.
LaRosa JC; Grundy SM; Waters DD; Shear C; Barter P; Fruchart JC; Gotto AM; Greten H; Kastelein JJ; Shepherd J; Wenger NK;
N Engl J Med; 2005 Apr; 352(14):1425-35. PubMed ID: 15755765
[TBL] [Abstract][Full Text] [Related]
8. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial.
Colhoun HM; Betteridge DJ; Durrington PN; Hitman GA; Neil HA; Livingstone SJ; Thomason MJ; Mackness MI; Charlton-Menys V; Fuller JH;
Lancet; 2004 Aug 21-27; 364(9435):685-96. PubMed ID: 15325833
[TBL] [Abstract][Full Text] [Related]
9. [Compared with atorvastatin at the dose of 10 mg per day rosuvastatin was more effective to reach an LDL goal of < 1.00 g/l in high cardiovascular risk patients (ARIANE study)].
Danchin N; Chadarevian R; Gayet JL; Licour M; Valensi P
Ann Cardiol Angeiol (Paris); 2007 Apr; 56(2):82-7. PubMed ID: 17484092
[TBL] [Abstract][Full Text] [Related]
10. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial.
Pedersen TR; Faergeman O; Kastelein JJ; Olsson AG; Tikkanen MJ; Holme I; Larsen ML; Bendiksen FS; Lindahl C; Szarek M; Tsai J;
JAMA; 2005 Nov; 294(19):2437-45. PubMed ID: 16287954
[TBL] [Abstract][Full Text] [Related]
11. Effects of rosuvastatin and atorvastatin compared over 52 weeks of treatment in patients with hypercholesterolemia.
Olsson AG; Istad H; Luurila O; Ose L; Stender S; Tuomilehto J; Wiklund O; Southworth H; Pears J; Wilpshaar JW;
Am Heart J; 2002 Dec; 144(6):1044-51. PubMed ID: 12486429
[TBL] [Abstract][Full Text] [Related]
12. Baseline blood pressure, low- and high-density lipoproteins, and triglycerides and the risk of vascular events in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial.
Amarenco P; Goldstein LB; Callahan A; Sillesen H; Hennerici MG; O'Neill BJ; Rudolph AE; Simunovic L; Zivin JA; Welch KM;
Atherosclerosis; 2009 Jun; 204(2):515-20. PubMed ID: 18962621
[TBL] [Abstract][Full Text] [Related]
13. Atorvastatin: its clinical role in cerebrovascular prevention.
Gaspardone A; Arca M
Drugs; 2007; 67 Suppl 1():55-62. PubMed ID: 17910521
[TBL] [Abstract][Full Text] [Related]
14. Alirocumab as Add-On to Atorvastatin Versus Other Lipid Treatment Strategies: ODYSSEY OPTIONS I Randomized Trial.
Bays H; Gaudet D; Weiss R; Ruiz JL; Watts GF; Gouni-Berthold I; Robinson J; Zhao J; Hanotin C; Donahue S
J Clin Endocrinol Metab; 2015 Aug; 100(8):3140-8. PubMed ID: 26030325
[TBL] [Abstract][Full Text] [Related]
15. The efficacy of statin monotherapy uptitration versus switching to ezetimibe/simvastatin: results of the EASEGO study.
Roeters van Lennep HW; Liem AH; Dunselman PH; Dallinga-Thie GM; Zwinderman AH; Jukema JW
Curr Med Res Opin; 2008 Mar; 24(3):685-94. PubMed ID: 18226326
[TBL] [Abstract][Full Text] [Related]
16. Effect of atorvastatin in elderly patients with a recent stroke or transient ischemic attack.
Chaturvedi S; Zivin J; Breazna A; Amarenco P; Callahan A; Goldstein LB; Hennerici M; Sillesen H; Rudolph A; Welch MA;
Neurology; 2009 Feb; 72(8):688-94. PubMed ID: 18768917
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of atorvastatin in treating high risk patients to reach low density lipoprotein-cholesterol goals: the Treat to Target (TTT-Israel) Study.
Leibovitz E; Harats D; Gavish D
Isr Med Assoc J; 2002 Jun; 4(6):407-10. PubMed ID: 12073409
[TBL] [Abstract][Full Text] [Related]
18. Relative and cumulative effects of lipid and blood pressure control in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels trial.
Amarenco P; Goldstein LB; Messig M; O'Neill BJ; Callahan A; Sillesen H; Hennerici MG; Zivin JA; Welch KM;
Stroke; 2009 Jul; 40(7):2486-92. PubMed ID: 19461031
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of atorvastatin for achieving cholesterol targets after LDL-cholesterol based dose selection in patients with type 2 diabetes.
Ferrer-García JC; Sanchez-Ballester E; Albalat-Galera R; Berzosa-Sanchez M; Herrera-Ballester A
J Cardiovasc Pharmacol Ther; 2008 Sep; 13(3):183-8. PubMed ID: 18635754
[TBL] [Abstract][Full Text] [Related]
20. Effect of individualizing starting doses of a statin according to baseline LDL-cholesterol levels on achieving cholesterol targets: the achieve cholesterol targets fast with atorvastatin stratified titration (ACTFAST) study.
Martineau P; Gaw A; de Teresa E; Farsang C; Gensini GF; Leiter LA; Langer A;
Atherosclerosis; 2007 Mar; 191(1):135-46. PubMed ID: 16643923
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
